<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04134182</url>
  </required_header>
  <id_info>
    <org_study_id>KCRB16102019</org_study_id>
    <nct_id>NCT04134182</nct_id>
  </id_info>
  <brief_title>Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.</brief_title>
  <official_title>A Phase 2 Pilot Study of the Efficacy and Safety of Nivolumab and Ipilimumab in T1aN0M0 Renal Cell Carcinoma Patients Ineligible for Surgical Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kidney Cancer Research Bureau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kidney Cancer Research Bureau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this Phase 2 study is to evaluate the efficacy and safety of nivolumab, an&#xD;
      anti-PD-1 antibody, and ipilimumab, an anti-CTLA-4 antibody, in T1aN0M0 clear-cell RCC&#xD;
      patients ineligible for surgical treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgery remains the standard curative-intent therapy for localized renal cell carcinoma&#xD;
      (RCC). Thus, systemic therapy for RCC should still be considered only in patients who have&#xD;
      contraindications to surgery.&#xD;
&#xD;
      Results of Phase 3 CheckMate 214 study showed that a combination of nivolumab and ipilimumab&#xD;
      has a significant impact on tumor burden in intermediate- and poor-risk metastatic RCC&#xD;
      patients with a complete response rate of 11% (Motzer et al. Lancet Oncology 2019). Median&#xD;
      time to objective response was 2.8 months. Among all complete responders to nivolumab plus&#xD;
      ipilimumab in the intention-to-treat population, 5% achieved a complete response at the first&#xD;
      scan, whereas most converted from the partial response at a median of 6.9 months or from the&#xD;
      stable disease at a median of 11.3 months.&#xD;
&#xD;
      We hypothesize that this combination could completely eliminate primary tumors in patients&#xD;
      with small primary (less than 4 cm) ineligible for surgical treatment. There are no studies&#xD;
      evaluating checkpoint inhibitors in this setting in RCC patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 16, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response Rate</measure>
    <time_frame>16 weeks</time_frame>
    <description>percentage of patients with localized RCC who have no tumor in kidney</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>16 weeks</time_frame>
    <description>percentage of patients with localized RCC who have no tumor in kidney or tumor shrinkage more than 30%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year disease-free survival rate</measure>
    <time_frame>3 years</time_frame>
    <description>percentage of patients who are disease free at 3 years after treatment start</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year survival rate</measure>
    <time_frame>5 years</time_frame>
    <description>percentage of patients who are alive at 5 years after treatment start</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>16 weeks</time_frame>
    <description>percentage of patients who have adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Nivolumab + Ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a combination of ipilimumab, followed by nivolumab for 16 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>3 mg/kg intravenously every 2 weeks during 16 weeks</description>
    <arm_group_label>Nivolumab + Ipilimumab</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>1 mg/kg intravenously every 3 weeks for four doses</description>
    <arm_group_label>Nivolumab + Ipilimumab</arm_group_label>
    <other_name>Yervoy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Cytologically proven clear-cell RCC&#xD;
&#xD;
          2. CT-confirmed measurable primary tumor less than 4 cm and no evidence of extranodal&#xD;
             metastatic disease (T1aN0M0)&#xD;
&#xD;
          3. Inability to perform surgery for any reason (functional single kidney with a central,&#xD;
             high-complexity RCC, high risk of nephrectomy and dialysis, patients with complex&#xD;
             coagulation disorders, etc.) or preference of patient is to have no surgery for any&#xD;
             reason&#xD;
&#xD;
          4. No contradictions to nivolumab and ipilimumab&#xD;
&#xD;
          5. Age 18 or older&#xD;
&#xD;
          6. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. prior treatment for RCC&#xD;
&#xD;
          2. pregnant or nursing&#xD;
&#xD;
          3. history of serious hypertension, cardiac arrhythmia, congestive heart failure, angina&#xD;
             pectoris, or another severe cardiovascular disease (i.e., New York Heart Association&#xD;
             class III or IV)&#xD;
&#xD;
          4. evidence of metastatic disease&#xD;
&#xD;
          5. local and/or systemic infections requiring antibiotics within 28 days prior to study&#xD;
             entry&#xD;
&#xD;
          6. other malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ilya Tsimafeyeu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Kidney Cancer Research Bureau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ilya Tsimafeyeu, MD</last_name>
    <phone>+79265646581</phone>
    <email>kidneycancer@yandex.ru</email>
  </overall_contact>
  <location>
    <facility>
      <name>N.N. Blokhin Russian Cancer Research Center</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Volkova, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Russian Scientific Center of Roentgenoradiology</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rustem Gafanov, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2019</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

